Combined treatment with R848 and another immune adjuvant or checkpoint inhibitor, such as a PD-1/PD-L1 inhibitor, using sEVs as promising carriers, can be a convincing strategy to circumvent tumor growth in vivo, and immunotherapy holds practical significance in inhibiting PCa progression. This evidence concerns the gene CD274 and neoplasm.